MoneyWorks4Me

Epigral informs about press release

27 Jan 2025 Evaluate
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Epigral has informed that it enclosed a Press Release for Un-Audited Financial Results - Q3 FY2025. The said Press Release is also available at www.epigral.com in the Investor Relations section.

The above information is a part of company’s filings submitted to BSE.


Epigral Share Price

1231.80 23.35 (1.93%)
28-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
SRF 2594.80
BASF India 3848.00
Pidilite Inds. 1628.90
Tata Chemicals 656.55
Deepak Nitrite 1763.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: